Business Wire

DEWIZ-GOLF

20.10.2021 10:02:08 CEST | Business Wire | Press release

Share
Jesper Kärrbrink Appointed Chairman of deWiz Golf

deWiz Golf’s Board, including co-founders Christian Bergh and Markus Westerberg, has announced that Jesper Kärrbrink has been appointed new Chairman of the Board. Kärrbrink brings extensive experience from company leadership roles, currently as chairman of Green Jade Games and previously as CEO of, among others, Svenska Spel, Eniro, Euroflorist, Mr. Green, and Östersunds-Posten.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005415/en/

“On behalf of my co-founder Markus and deWiz's board, it is with great pride that I announce that Jesper has been appointed deWiz's new chairman of the board,” said Christian Bergh, co-founder and COO of deWiz Golf. “After five years of development and research, this has been an exciting year with the launch of deWiz and the future is even more exciting with executives like Jesper helping us guide us towards our strategic vision to revolutionize golf and other sports using our world-class wearable technology. Jesper's global experience will be of great value as deWiz expands across golf-rich markets, including North America, Europe and Asia.”

Launched this summer, deWiz is based on revolutionary wearable technology that combines capturing high-precision data of a golfer's swing in real time and biometric feedback to increase a golfer's pace of learning and consistency.

“deWiz is the perfect example of how technology can help players improve their golf game - at all levels,” said Jesper Kärrbrink, new chairman of deWiz Golf. “Artificial intelligence, data collection and motion sensors have been used for a long time to help elite athletes improve their performance. And what's really fascinating about deWiz is how it delivers this high-tech approach at my level, as a dedicated amateur golfer, through a wearable device that helps me to improve my game anywhere, whether I'm on the course, on the range or practicing on my swing at home.”

Today, golfers in the EU, North America and South Korea can buy deWiz and the company plans to expand with new markets in 2022, including Japan, Australia and South Africa.

DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz has been under development for more than five years and has attracted an impressive list of ambassadors, including Bryson DeChambeau, U.S. Open champion from 2020; Annika Sorenstam, 10-time major-champion; Vijay Singh, 3-time major-champion; Lydia Ko, 2-time major champion; 2016 Open-champion Henrik Stenson; 2019 Houston Open-champion Lanto Griffin; and 2-time world champion in long drive, Tim Burke. deWiz's user-friendly app and wearable technology tracks the exact position of a golfer's hands throughout the swing, providing a 3D analysis and delivers data showing Transition , Backswing Length , Wedge Distance and Tempo . These unique deWiz data points provide measurable values ​​that any avid golfer, professional teacher or world-class player can use to effectively refine their swing. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world increase their enjoyment of the game through innovative technology that increases their pace of learning. At the moment, deWiz sells for $699 and is available in the U.S., Canada, Europe and South Korea (more markets are opening regularly - visit the site for the latest updates). Visit dewizgolf.com for more information on how to improve your swing faster or download the app to demonstrate its features via the Apple App Store or Google Play.

Link:

ClickThru

Social Media:

https://www.facebook.com/dewizgolf

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye